Mental health struggles like stress, anxiety, and depression are common for women living with breast cancer. These feelings can make daily life harder and affect how well a patient feels overall. This research matters because it explores whether new digital tools can help. Many people face barriers to seeing a therapist, such as long wait times or travel difficulties. Digital tools could offer a helpful way to get support when traditional care is hard to reach. This study brings together results from many different trials to see if these new methods work better than older ones.
The researchers examined data from randomized controlled trials involving approximately 7,551 women with breast cancer. These trials compared digital and AI-supported interventions, which included cognitive behavioral therapy, mindfulness, and psychoeducation, against static or minimally interactive platforms. Some of the digital tools used artificial intelligence to tailor content or blend online support with human guidance. The goal was to see if these modern approaches could reduce distress and improve how patients feel about their health and daily life.
The results showed modest but consistent reductions in stress, anxiety, and depressive symptoms among women using the digital tools. Health-related quality of life also improved for those in the intervention groups. The effect sizes were measured using standardized differences, indicating that while the changes were real, they were not dramatic. Blended formats that combined AI assistance with human support and fully AI-assisted formats tended to show stronger effects than simple static platforms. This suggests that adding some level of interactivity or personalization may make a difference.
No serious adverse events or discontinuations were reported in the studies included in this review. The interventions appeared to be well-tolerated by the participants. However, the safety data relied on self-reports from the original trials, and long-term safety was not fully explored because the follow-up periods were short. This means we do not yet know if these tools could cause problems over many years of use.
It is important not to overstate what this single review proves. The evidence certainty remains moderate due to several limitations. The studies varied greatly in their design, and many were conducted in small, single-center samples. There was minimal cultural adaptation, and few participants came from low- or middle-income countries. Because of this, the results may not apply to everyone everywhere. Also, the short follow-up periods mean we do not know if the benefits last. For now, these digital tools may serve as helpful additions to conventional care, but they should not replace standard medical treatment. Patients should discuss these options with their healthcare team to see if they fit their specific situation.